Rayner CK, Wu T, Aroda VR, et al. - This study was sought to compare gastrointestinal adverse event (AE) rates for iGlarLixi vs glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) during the first 12 weeks of therapy, including sensitivity analysis with IDegLira. Researchers applied the PICO framework to find studies in MEDLINE, Embase, and CENTRAL searches applying a proprietary, web‐based, standardized tool with single data extraction. The data revealed that iGlarLixi generally correlated with less nausea and vomiting vs single‐agent GLP‐1 RAs during the first 12 weeks of treatment. The results considered that improved gastrointestinal tolerability with fixed‐ratio combinations may favor treatment persistence.